Published in J Virol on May 01, 2004
Epstein-Barr virus entry. J Virol (2007) 2.28
Herpes virus fusion and entry: a story with many characters. Viruses (2012) 2.05
Fusion of epithelial cells by Epstein-Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins alphavbeta6 or alphavbeta8. Proc Natl Acad Sci U S A (2009) 1.79
Crystal structure of the Epstein-Barr virus (EBV) glycoprotein H/glycoprotein L (gH/gL) complex. Proc Natl Acad Sci U S A (2010) 1.75
Cell-surface expression of a mutated Epstein-Barr virus glycoprotein B allows fusion independent of other viral proteins. Proc Natl Acad Sci U S A (2004) 1.72
The amino terminus of Epstein-Barr virus glycoprotein gH is important for fusion with epithelial and B cells. J Virol (2005) 1.70
Characterization of human cytomegalovirus glycoprotein-induced cell-cell fusion. J Virol (2005) 1.56
Soluble Epstein-Barr virus glycoproteins gH, gL, and gp42 form a 1:1:1 stable complex that acts like soluble gp42 in B-cell fusion but not in epithelial cell fusion. J Virol (2006) 1.48
Point mutations in EBV gH that abrogate or differentially affect B cell and epithelial cell fusion. Virology (2007) 1.39
Epstein-Barr virus shed in saliva is high in B-cell-tropic glycoprotein gp42. J Virol (2006) 1.38
Mutations of Epstein-Barr virus gH that are differentially able to support fusion with B cells or epithelial cells. J Virol (2005) 1.34
Binding-site interactions between Epstein-Barr virus fusion proteins gp42 and gH/gL reveal a peptide that inhibits both epithelial and B-cell membrane fusion. J Virol (2007) 1.22
Antibodies to gp350/220 enhance the ability of Epstein-Barr virus to infect epithelial cells. J Virol (2006) 1.14
Herpes simplex virus glycoproteins H/L bind to cells independently of {alpha}V{beta}3 integrin and inhibit virus entry, and their constitutive expression restricts infection. J Virol (2010) 1.13
Epstein-Barr Virus (EBV)-associated gastric carcinoma. Viruses (2012) 1.12
The KGD motif of Epstein-Barr virus gH/gL is bifunctional, orchestrating infection of B cells and epithelial cells. MBio (2012) 1.12
Comparative analysis of gO isoforms reveals that strains of human cytomegalovirus differ in the ratio of gH/gL/gO and gH/gL/UL128-131 in the virion envelope. J Virol (2013) 1.11
Mapping the N-terminal residues of Epstein-Barr virus gp42 that bind gH/gL by using fluorescence polarization and cell-based fusion assays. J Virol (2010) 1.05
The Epstein-Barr virus BMRF-2 protein facilitates virus attachment to oral epithelial cells. Virology (2007) 1.03
Epstein-Barr virus transcytosis through polarized oral epithelial cells. J Virol (2013) 1.01
Laser-capture microdissection of oropharyngeal epithelium indicates restriction of Epstein-Barr virus receptor/CD21 mRNA to tonsil epithelial cells. J Oral Pathol Med (2008) 1.00
Integrins as triggers of Epstein-Barr virus fusion and epithelial cell infection. Virulence (2010) 0.99
Analysis of Epstein-Barr virus reservoirs in paired blood and breast cancer primary biopsy specimens by real time PCR. Breast Cancer Res (2006) 0.97
Important but differential roles for actin in trafficking of Epstein-Barr virus in B cells and epithelial cells. J Virol (2011) 0.94
Analysis of Epstein-Barr virus glycoprotein B functional domains via linker insertion mutagenesis. J Virol (2008) 0.94
Epstein-Barr virus glycoprotein gB and gHgL can mediate fusion and entry in trans, and heat can act as a partial surrogate for gHgL and trigger a conformational change in gB. J Virol (2014) 0.91
Functional homology of gHs and gLs from EBV-related gamma-herpesviruses for EBV-induced membrane fusion. Virology (2007) 0.89
Oral dysplasia and squamous cell carcinoma: correlation between increased expression of CD21, Epstein-Barr virus and CK19. Oral Oncol (2012) 0.87
Compatibility of the gH homologues of Epstein-Barr virus and related lymphocryptoviruses. J Gen Virol (2007) 0.84
Epstein-Barr virus infection mechanisms. Chin J Cancer (2014) 0.83
EBV infection is common in gingival epithelial cells of the periodontium and worsens during chronic periodontitis. PLoS One (2013) 0.83
The BDLF2 protein of Epstein-Barr virus is a type II glycosylated envelope protein whose processing is dependent on coexpression with the BMRF2 protein. Virology (2008) 0.83
The conserved disulfide bond within domain II of Epstein-Barr virus gH has divergent roles in membrane fusion with epithelial cells and B cells. J Virol (2014) 0.80
Modeling the dynamics of virus shedding into the saliva of Epstein-Barr virus positive individuals. J Theor Biol (2012) 0.79
EBV glycoproteins: where are we now? Future Virol (2016) 0.77
The BDLF3 gene product of Epstein-Barr virus, gp150, mediates non-productive binding to heparan sulfate on epithelial cells and only the binding domain of CD21 is required for infection. Virology (2016) 0.75
Epithelial cell retention of transcriptionally active, P3HR-1-derived heterogeneous Epstein-Barr virus DNA with concurrent loss of parental virus. J Virol (2011) 0.75
A herpes simplex virus mutant in which glycoprotein D sequences are replaced by beta-galactosidase sequences binds to but is unable to penetrate into cells. J Virol (1988) 7.80
Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A (1984) 6.62
Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med (1984) 4.47
Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med (2002) 4.33
Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell (1987) 3.87
Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci U S A (1980) 3.77
Identification and characterization of the Epstein-Barr virus receptor on human B lymphocytes and its relationship to the C3d complement receptor (CR2). J Virol (1985) 3.76
Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int J Cancer (1984) 3.49
Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes. J Virol (1997) 3.23
The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells. J Virol (1995) 3.16
Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes. Proc Natl Acad Sci U S A (1984) 2.71
Epstein-Barr virus uses different complexes of glycoproteins gH and gL to infect B lymphocytes and epithelial cells. J Virol (1998) 2.71
Epstein-Barr virus infection and replication in a human epithelial cell system. Nature (1992) 2.62
Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol (1998) 2.61
Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells. J Virol (2000) 2.34
Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect. J Virol (1998) 2.34
A monoclonal antibody to glycoprotein gp85 inhibits fusion but not attachment of Epstein-Barr virus. J Virol (1988) 2.29
Different functional domains in the cytoplasmic tail of glycoprotein B are involved in Epstein-Barr virus-induced membrane fusion. Virology (2001) 2.25
Epstein-Barr virus infection of polarized tongue and nasopharyngeal epithelial cells. Nat Med (2003) 2.21
Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication. J Virol (1999) 2.17
Epstein-Barr virus glycoprotein gp85 associates with the BKRF2 gene product and is incompletely processed as a recombinant protein. Virology (1993) 2.09
Epstein-Barr virus enters B cells and epithelial cells by different routes. J Virol (1992) 2.07
The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation. J Virol (1996) 1.93
Identification of a human epithelial cell surface protein sharing an epitope with the C3d/Epstein-Barr virus receptor molecule of B lymphocytes. Int J Cancer (1989) 1.76
Depletion of glycoprotein gp85 from virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells. J Virol (1989) 1.75
Epstein-Barr virus entry utilizing HLA-DP or HLA-DQ as a coreceptor. J Virol (2000) 1.65
Replication of EBV in epithelial cells during infectious mononucleosis. Nature (1977) 1.61
Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism. Science (1992) 1.58
Identification of Epstein-Barr virus-infected cells in tonsils of acute infectious mononucleosis by in situ hybridization. Hum Pathol (1989) 1.52
Patterns of Epstein-Barr virus infection in non-neoplastic lymphoid tissue. Blood (1992) 1.51
CD21-Dependent infection of an epithelial cell line, 293, by Epstein-Barr virus. J Virol (1999) 1.39
Epstein-Barr virus lacking glycoprotein gp85 cannot infect B cells and epithelial cells. Virology (2000) 1.30
Epstein--Barr virus-induced cell fusion. Nature (1980) 1.29
CR2 ligands modulate human B cell activation. J Immunol (1988) 1.18
Host cell requirements for efficient infection of quiescent primary B lymphocytes by Epstein-Barr virus. J Virol (1995) 1.12
Co-expression of the Epstein-Barr virus BXLF2 and BKRF2 genes with a recombinant baculovirus produces gp85 on the cell surface with antigenic similarity to the native protein. J Gen Virol (1995) 1.10
Persistence of Epstein-Barr virus in salivary gland biopsies from healthy individuals and patients with Sjögren's syndrome. Clin Exp Immunol (1989) 1.01
Tight binding of influenza virus hemagglutinin to its receptor interferes with fusion pore dilation. J Virol (2002) 0.96
Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med (2002) 4.33
Fusion of epithelial cells by Epstein-Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins alphavbeta6 or alphavbeta8. Proc Natl Acad Sci U S A (2009) 1.79
A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation. Transplantation (2009) 1.77
The Epstein-Barr virus BFRF1 and BFLF2 proteins interact and coexpression alters their cellular localization. Virology (2004) 1.54
Point mutations in EBV gH that abrogate or differentially affect B cell and epithelial cell fusion. Virology (2007) 1.39
Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion. J Virol (2005) 1.36
Mutations of Epstein-Barr virus gH that are differentially able to support fusion with B cells or epithelial cells. J Virol (2005) 1.34
Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition. Proc Natl Acad Sci U S A (2003) 1.20
Antibodies to gp350/220 enhance the ability of Epstein-Barr virus to infect epithelial cells. J Virol (2006) 1.14
Epstein-Barr virus LF2: an antagonist to type I interferon. J Virol (2008) 1.03
Spectral content of the intraocular pressure pulse wave: glaucoma patients versus normal subjects. Graefes Arch Clin Exp Ophthalmol (2002) 0.98
Important but differential roles for actin in trafficking of Epstein-Barr virus in B cells and epithelial cells. J Virol (2011) 0.94
αvβ3-integrin is a major sensor and activator of innate immunity to herpes simplex virus-1. Proc Natl Acad Sci U S A (2012) 0.92
Association between human papilloma virus/Epstein-Barr virus coinfection and oral carcinogenesis. J Oral Pathol Med (2014) 0.91
Atom-scale ptychographic electron diffractive imaging of boron nitride cones. Phys Rev Lett (2012) 0.91
Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro. J Virol (2002) 0.88
Oral dysplasia and squamous cell carcinoma: correlation between increased expression of CD21, Epstein-Barr virus and CK19. Oral Oncol (2012) 0.87
Primary CD4+ T-cell responses provide both helper and cytotoxic functions during Epstein-Barr virus infection and transformation of fetal cord blood B cells. J Virol (2007) 0.86
Compatibility of the gH homologues of Epstein-Barr virus and related lymphocryptoviruses. J Gen Virol (2007) 0.84
Epstein-Barr virus infection mechanisms. Chin J Cancer (2014) 0.83
The BDLF2 protein of Epstein-Barr virus is a type II glycosylated envelope protein whose processing is dependent on coexpression with the BMRF2 protein. Virology (2008) 0.83
Comparative chronic toxicity of nanoparticulate and ionic zinc to the earthworm Eisenia veneta in a soil matrix. Environ Int (2011) 0.81
The B subunit of Escherichia coli heat-labile enterotoxin enhances CD8+ cytotoxic-T-lymphocyte killing of Epstein-Barr virus-infected cell lines. J Virol (2003) 0.81
Morphometry of the epidermis of an invasive megascoelecid earthworm (Amynthas gracilis, Kinberg 1867) inhabiting actively volcanic soils in the Azores archipelago. Ecotoxicol Environ Saf (2010) 0.78
Laser capture microdissection for analysis of gene expression in formalin-fixed paraffin-embedded tissue. Methods Mol Biol (2011) 0.78
Contrast in atomically resolved EF-SCEM imaging. Ultramicroscopy (2013) 0.77
Epstein-Barr virus neutralizing antibody levels and risk of multiple sclerosis. Mult Scler (2012) 0.77
The B subunit of Escherichia coli enterotoxin helps control the in vivo growth of solid tumors expressing the Epstein-Barr virus latent membrane protein 2A. Cancer Med (2015) 0.76
Bright-field scanning confocal electron microscopy using a double aberration-corrected transmission electron microscope. Ultramicroscopy (2010) 0.76
Regional variability in visual field sensitivity during hypercapnia. Am J Ophthalmol (2003) 0.75
The Edward Jenner Society: a new academic society for vaccinologists. Vaccine (2010) 0.75